Martin Landray, who is Professor of Medicine and Epidemiology at Oxford University and co-chief investigator of the RECOVERY clinical trial, summed up RECOVERY

Martin Landray, who is Professor of Medicine and Epidemiology at Oxford University and co-chief investigator of the RECOVERY clinical trial, summed up RECOVERY in a few tweets [1]: - 40,000 patients enrolled in the clinical trial Treatments that benefit hospitalised patients: - Dexamethasone: reduces mortality for patients requiring oxygen or mechanical ventilator - Tocilizumab: reduces mortality for patients with inflammation (raised CRP - C-reactive protein) and requiring oxygen or ventilator - Monoclonal antibody combination reduces deaths for hospitalised patients with COVID-19 who haven't produced antibodies for themselves Treatments that have no benefit for hospitalised patients: - Hydroxychloroqine - Lopinavir-ritonavir - Azithromycin - Convalescent plasma - Colchicine - Aspirin [1] https://twitter.com/MartinLandray/status/1403336521378406403 https://twitter.com/MartinLandray/status/1403336521378406403